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Abstract
Chronic obstructive pulmonary disease (COPD) may cause significant symptoms and have an impact
on survival. Smoking is an important risk factor for COPD and is common in candidates for liver
transplantation; however, the risk factors for and outcomes of COPD in this population are unknown.
We performed a prospective cohort study of 373 patients being evaluated for liver transplantation at
7 academic centers in the United States. COPD was characterized by expiratory airflow obstruction
and defined as follows: prebronchodilator forced expiratory volume in 1 second/forced vital capacity
< 0.70. Patients completed the Liver Disease Quality of Life Questionnaire 1.0, which included the
Short Form-36. The mean age of the study sample was 53 ± 9 years, and 234 (63%) were male. Sixty-
seven patients (18%, 95% confidence interval 14%–22%) had COPD, and 224 (60%) had a history
of smoking. Eighty percent of patients with airflow obstruction did not previously carry a diagnosis
of COPD, and 27% were still actively smoking. Older age and any smoking (odds ratio = 3.74, 95%
confidence interval 1.94–7.23, P < 0.001) were independent risk factors for COPD. Patients with
COPD had worse New York Heart Association functional class and lower physical component
summary scores on the 36-Item Short Form but had short-term survival similar to that of patients
without COPD. In conclusion, COPD is common and often undiagnosed in candidates for liver
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transplantation. Older age and smoking are significant risk factors of COPD, which has adverse
consequences on functional status and quality of life in these patients.
Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow
limitation that is not fully reversible. The physiologic changes associated with COPD lead to
dyspnea, exercise limitation, susceptibility to infections and exacerbations, and significant
morbidity and mortality. Patients with advanced liver disease have well-known abnormalities
in pulmonary function. Lung volumes are commonly decreased by hepatomegaly, ascites, basal
atelectasis, or pleural effusions.1–5 Screening studies of patients with chronic liver disease
have demonstrated arterial blood gas abnormalities in as many as 45%.2 However, little is
known about the prevalence, risk factors, and impact of COPD in patients with advanced liver
disease considered for liver transplantation (LT).
Smoking is the most important risk factor for COPD in the general population and is commonly
reported by patients with advanced liver disease. Smoking may also contribute to the severity
of various liver diseases and hepatocellular carcinoma.6–8 Smoking and COPD may be
particularly important in patients with advanced liver disease being evaluated for LT, for whom
perioperative outcomes and postoperative recovery could be compromised and long-term
interactions with immunosuppression are unknown.
Therefore, we aimed to determine the prevalence and predictors of COPD in patients with
advanced liver disease evaluated for LT. We hypothesized that smoking would be not only
common but also a strong predictor of COPD. We also aimed to determine the impact of COPD
on functional status, health-related quality of life, and overall survival.
PATIENTS AND METHODS
Study Design and Study Sample
The Pulmonary Vascular Complications of Liver Disease study enrolled a cohort of 536
patients evaluated for LT at 7 centers in the United States between 2003 and 2006.9 The cohort
included patients with clinical portal hypertension and excluded patients who had evidence of
active infection or recent (<2 weeks) gastrointestinal bleeding or who had previously
undergone liver or lung transplantation. The sample for this study included newly evaluated
patients in the cohort with available prebronchodilator spirometry and data regarding smoking
status.
Data Collection
Demographic information was collected from each patient; age was categorized by quartiles
for the analysis. Data regarding the etiology of underlying liver disease, past medical history,
and social history were recorded. Patients underwent a physical examination that included
anthropometry and blood pressure measurements and underwent a laboratory assessment. The
Model for End-Stage Liver Disease (MELD) score was calculated.10
Chest radiography was interpreted locally at each center. Spirometry, lung volumes, and
diffusing capacity for carbon monoxide were measured; results are expressed with standard
gender- and race-specific prediction equations where appropriate.11–13 Arterial blood gas
sampling was performed on room air in the seated position. Contrast transthoracic
echocardiography was performed and interpreted at each center. Agitated saline was injected
via a peripheral vein during imaging. The appearance of microbubbles in the left heart after 3
or more cardiac cycles (late) after venous injection of agitated saline was considered to indicate
intrapulmonary shunting. The appearance of microbubbles in the left heart after fewer than 3
cardiac cycles (early) after venous injection was considered to indicate intracardiac shunting.
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The presence of hepatopulmonary syndrome was defined by (1) contrast echocardiography
with late appearance of microbubbles after venous injection of agitated saline and (2) an
alveolar-arterial oxygen gradient ≥ 15 mm Hg (or ≥ 20 mm Hg if age > 64 years).14 Significant
pulmonary hypertension was defined as right ventricular systolic pressure (RVSP) > 50 mm
Hg by echocardiography (if estimable).
We administered the Liver Disease Quality of Life Questionnaire 1.0.15 This is a validated
questionnaire that not only includes questions specific to advanced liver disease but also
includes the Medical Outcomes Study Short Form-36 (SF-36; version 2.0).16 Patients either
completed the questionnaire during their visit to the clinical center or returned the questionnaire
by mail.
The study was approved by the institutional review board of each center, and patients provided
informed consent before undergoing study procedures.
COPD Definition
COPD was defined with modified Global Initiative on Obstructive Lung Disease criteria as
follows: prebronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity
(FVC) < 0.70.17 Mild COPD was defined as FEV1 % predicted ≥ 80%, moderate as FEV1 %
predicted ≥ 50% and < 80%, severe as FEV1 % predicted ≥ 30% and < 50%, and very severe
as FEV1 % predicted < 30%.
Statistical Analysis
Continuous data were summarized as mean ± standard deviation or median (interquartile
range). Categorical variables were summarized as n (%). Unpaired Student t tests, Wilcoxon
rank sum tests, chi-square tests, and Fisher’s exact tests were used as appropriate. Bivariate
logistic regression was performed with COPD status as the dependent variable and potential
predictors as independent variables, with results expressed as odds ratios (ORs). Multivariate
logistic regression was performed, including all variables that had P values < 0.20 on bivariate
analysis or were hypothesized to predict case status. With the number of cases, we determined
that the final multivariate model should include 4 or fewer predictors to prevent overfitting.
The final multivariate model was assessed with the Hosmer-Lemeshow goodness-of-fit test;
dbetas were calculated to assess influential subjects. Proportional hazards regression models
were used for survival analyses.
All analyses were performed with Stata/IC version 10.0 (StataCorp, College Park, TX). A 2-
sided P value of <0.05 was considered statistically significant.
RESULTS
Of 536 patients in the entire cohort, 473 (88%) patients were undergoing a new evaluation for
LT. Of these, 373 (79%) had pulmonary function testing and available smoking history
recorded, and they composed the study sample. The study sample was similar to the excluded
patients [new LT evaluations without pulmonary function or smoking data (n = 100)] in terms
of age, gender, and MELD score (data not shown). Excluded patients were more likely to be
non-Hispanic white (92%) than included patients (79%).
The mean age of the study sample was 53 ± 9 years, and 234 (63%) were male. Two hundred
ninety-three (79%) were non-Hispanic white, 39 (10%) were Hispanic, and 22 (6%) were non-
Hispanic black. Sixty-seven patients [18%, 95% confidence interval (CI) 14%–22%] had
COPD. Eighteen (29%) had mild COPD, 39 (58%) had moderate COPD, 8 (12%) had severe
COPD, and 2 (3%) had very severe COPD. Patients with COPD were somewhat older than
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patients without COPD and tended to be male (Table 1). COPD patients were somewhat less
likely to be Hispanic white.
There were significant differences in the etiology of liver disease between patients with and
without COPD (Table 1); patients may have had more than 1 etiology of liver disease. Patients
with COPD were significantly more likely than those without it to have alcohol-related liver
disease. Those without COPD tended to have more nonalcoholic fatty liver disease, primary
sclerosing cholangitis (PSC), or primary biliary cirrhosis (PBC) in comparison with those with
COPD. The groups were similar in terms of hepatitis C infection and alpha-1-antitrypsin
deficiency–related liver disease. We had available genotyping on 5 patients with reported
alpha-1-antitrypsin deficiency (all non-COPD), which showed the ZZ genotype in only 1
patient. The severity of liver dysfunction appeared similar between the groups, as reflected by
the MELD score, and the median time from diagnosis of liver disease to referral for LT
evaluation was 3 years in both groups.
Patients with COPD were more likely to have a history of ascites than those without COPD
(P = 0.018; Table 2). Other liver disease complications and the prevalence of diabetes,
hypertension, coronary artery disease, and other medical comorbidities were not different
between the groups (data not shown). Notably, 80% of patients with COPD by spirometry had
this diagnosis first made at the time of LT evaluation.
Eighty-one percent of patients with COPD had ever smoked versus 56% of those without
COPD (P = 0.001; Table 2). Of the COPD patients who were ever-smokers, more than one-
quarter (27%) reported active smoking at the time of their LT evaluation. For those who were
ever smokers with available pack-year data (n = 131), 20 pack years or more of smoking was
associated with a dramatically increased risk of COPD in comparison with those with a lesser
smoking history (OR = 4.17, 95% CI 1.12–15.47, P = 0.033). For all patients with smoking
status and pack-year data (n = 280), 20 pack years or more of smoking continued to show a
very significant increased risk of COPD versus fewer pack years or no smoking history (OR
= 6.09, 95% CI 2.97–12.48, P = 0.001). Alcohol use was also associated with an increased risk
of COPD (P = 0.008).
Patients with COPD had a significantly lower body mass index in comparison with patients
without COPD (27 ± 6 kg/m2 versus 29 ± 6 kg/m2, respectively, P = 0.004; Table 3). There
were no other differences in physical examination or laboratory values.
By definition, pulmonary function varied significantly between the 2 groups (Table 4). Patients
with COPD had significantly lower FEV1 % predicted, FEV1/FVC, and (in whom it was
measured) diffusing capacity for carbon monoxide and higher alveolar-arterial oxygen
gradients (all P < 0.05). Chest radiography and most echocardiographic measurements were
similar between the 2 groups (Table 5). However, patients with COPD had significantly higher
estimated RVSP than patients without COPD and more commonly had significant pulmonary
hypertension [RVSP > 50 mm Hg; COPD = 9 (24%) versus no COPD = 20 (10%), P = 0.02,
n = 230]. Imputing low RVSP estimates for those patients with transthoracic echocardiography
with missing RVSP estimates did not change these findings (data not shown). Approximately
60% of both COPD and non-COPD patients demonstrated intrapulmonary shunting; 3 (27%)
patients with COPD and 69 (33%) patients without COPD (with complete data) had
hepatopulmonary syndrome (P = 1.0, n = 218).
Multivariate Analysis
We assessed variables from Tables 1 and 2 in multivariate logistic regression. Older age and
any smoking were independently associated with an increased risk of COPD (Table 6). Alcohol
use and etiology of liver disease were no longer associated with the risk of COPD in our
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adjusted model and were likely confounded by smoking. Race/ethnicity and gender were not
found to be predictors of COPD in our study sample. There were no significant interactions
between the final factors in the model. The model fit was adequate (P = 0.51), and there were
no particularly influential subjects.
Functional Status, Quality of Life, and Socioeconomic Status
Overall, patients with COPD had worse New York Heart Association functional class than
patients without COPD (Table 7). Of the 373 patients in the study sample, 214 completed the
Liver Disease Quality of Life Questionnaire 1.0. Patients who returned the questionnaire were
similar to those from the study sample who did not in terms of age, gender, race/ethnicity,
MELD score, smoking, and probability of COPD (data not shown). There were no differences
in the liver disease–specific scales between patients with and without COPD (data not shown).
However, patients with COPD scored lower than non-COPD patients on the physical
component summary score of the SF-36 questionnaire, indicating worse quality of life (31 ±
10 versus 35 ± 12, respectively, P = 0.047, n = 209) Adjustment for age did not affect these
results. There were no differences in marital status, educational status, or income between the
2 groups (data not shown).
LT and Survival
Two hundred four patients in the study sample were listed for LT. Patients with COPD were
significantly less likely to be listed for LT than patients without COPD [28 (42%) versus 176
(58%), respectively, P = 0.019]. Of the patients with COPD who were listed for LT, 39% had
mild COPD, 50% had moderate COPD, 11% had severe COPD, and none had very severe
COPD. Patients with COPD who were denied listing for LT had significantly more severe
disease than patients with COPD who were listed (P = 0.01). One hundred thirteen (30%)
patients in the study sample underwent LT; there were no differences in performance of LT
between patients with and without COPD (data not shown).
All patients were followed until December 31, 2006; there were no patients lost-to follow-up.
The 1-year survival of the entire cohort was 87% (95% CI 83%–90%), and there were 81 deaths
overall. The median follow-up time was 601 days (interquartile range, 390–1319 days).
Patients with COPD had a survival similar to that of patients without COPD overall (hazard
ratio = 1.0, 95% CI 0.50–1.70, P = 0.89); adjustment for the performance of LT did not change
this result. The severity of COPD was not associated with the risk of death in the study sample
(data not shown). We found no difference between groups in post-LT survival (hazard ratio =
0.50, 95% CI 0.06–3.70, P = 0.48). Similarly, there was no association between smoking and
overall or posttransplant mortality (data not shown).
DISCUSSION
To the best of our knowledge, this is the largest prospective, multicenter cohort study of lung
function ever performed in candidates for LT. We have shown that 18% of new patients
undergoing LT evaluation in the United States have COPD. Older age and any history of
smoking increase the risk of COPD in this population. Notably, 27% of patients with COPD
reported active smoking, and 80% had the diagnosis of COPD made for the first time during
their LT evaluation. In addition, COPD was associated with a worse New York Heart
Association functional class and with a worse quality of life in terms of physical limitations.
Despite the impact on functional status and quality of life, COPD did not significantly affect
survival.
The prevalence of COPD in the LT candidates in our study was greater than the prevalence in
the general population found in some studies and similar to that found in others.18–20 The
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COPD prevalence in our study was greater than that found in older, smaller studies performed
in LT candidates; however, differences between our study population and the others may
explain these findings. In 1991, Hourani et al.2 published a study of 116 consecutive patients
admitted for evaluation for LT and found that 7% had obstruction by spirometry (defined as
FEV1/FVC less than 2 standard deviations below the predicted value). Although 55% of these
patients were current or former smokers, the mean age was 45 years, and most patients were
female, in contrast to our cohort, which was some 10 years older on average and mostly male.
In addition, only 8% of the study population of Hourani et al. had cirrhosis due to alcohol; this
was a much lower prevalence than that in our study. Another study found a prevalence of
obstruction of 12% by spirometry in 58 patients listed for LT.4 Of note, this study excluded
symptomatic patients and patients who were evaluated but not listed for LT. This cohort had
a smoking prevalence of 29%, included mostly females, and included mostly patients with
PBC and PSC. Krowka et al.3 studied 95 patients who underwent LT who had preoperative
and postoperative pulmonary function testing. Although 75% of these patients had either PBC
or PSC, these investigators found that 17% had an FEV1/FVC ratio <75%, which did not
change after LT.
It may be difficult to generalize the prevalence and risk factors for COPD from these studies.
The most common modern indications for LT evaluation are alcohol-related liver disease and
hepatitis C infection, which affect very different populations in terms of age and gender in
comparison with those included in these older studies. Importantly, gender and alcohol use are
tightly related to smoking, so our results are likely much more applicable to the LT population
evaluated in the United States in the modern era.
Patients with advanced liver disease commonly demonstrate coexistent restriction due to
hepatomegaly and ascites, which could increase the FEV1/FVC ratio.1,2,5 Therefore, it is
possible that we have underestimated the actual prevalence of COPD in our cohort. On the
other hand, some studies have shown that diuresis or large-volume paracentesis in patients with
tense ascites increases FEV1 and FVC in parallel with an unchanged FEV1/FVC ratio.21,22
Less than 50% of patients in our study had detectable ascites by physical examination, and this
makes it less likely that this had a significant impact on our conclusions.
The most important contributor to the increased prevalence of COPD in this population was
smoking, which was reported by 81% of the patients with COPD and 56% of the study sample
overall. Others have shown virtually identical frequencies of smoking in patients with advanced
liver disease.2,23 These smoking rates are significantly higher than those seen in the general
population, and this is likely attributable to the association between smoking and other habits
predisposing to advanced liver disease, such as chronic alcohol use and intravenous drug use.
The increased risk for older patients in our study may be due to either age-related changes in
lung function or residual confounding by pack years (that is, older age potentially represents
more years of smoking). Although we recorded collected information on pack years, these data
were incomplete and may suffer from misclassification.
In addition to the impact of smoking on COPD, studies have also shown that tobacco use is
associated with increased severity of liver fibrosis,6 hepatocellular carcinoma,7 and hepatic
lesions in patients with hepatitis C infection.8 There is also evidence to indicate that patients
with a history of smoking have an increased risk for posttransplant complications.23 We did
not find differences in overall survival or post-transplant survival by smoking status; however,
we neither assessed perioperative outcomes (such as length of stay) nor had sufficient numbers
of transplanted patients and length of follow-up to assess post-LT complications, such as
neoplasm. Studies have found increased risks of various cancers in patients with alcohol-related
liver disease undergoing LT in comparison with others.24,25 This association may very well
be confounded by smoking, which is more likely responsible for many of these cancers.
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Patients with COPD had higher RVSP by transthoracic echocardiography and more commonly
had significant pulmonary hypertension in comparison with patients without COPD. This may
be explained by ventilation-perfusion mismatch and local hypoxic vasoconstriction, hypoxia-
related pulmonary vascular remodeling, parenchymal destruction, or elevated cardiac output
or pulmonary venous pressure. Although there were no differences between COPD and non-
COPD patients in terms of the partial pressure of oxygen or oxygen saturation in arterial blood,
there was a significant difference in the alveolar-arterial oxygen gradient. Because right heart
catheterization was not routinely performed in these patients, it is difficult to know whether
the pulmonary hypertension in these patients was attributable to the lung disease itself or to a
cardiac etiology. It is certainly possible, however, that the pulmonary hypertension in patients
with COPD contributed to the functional limitation, although there were no differences in right-
sided cardiac morphology attributable to COPD. It should be noted that it is unknown whether
these patients had portopulmonary hypertension, which requires invasive hemodynamic
measurement and the absence of other significant cardiac or pulmonary disease for diagnosis.
Chronic liver disease is associated with reduced quality of life, notwithstanding other comorbid
conditions.26 Even so, COPD had a significant additional negative impact not only on
functional class but also on quality of life in our cohort. LT candidates with COPD had more
impairment in the performance of usual physical activities, as reflected by the SF-36 physical
component score. Considering this already severely compromised patient population, we
believe that the treatment of COPD and smoking cessation are likely important for a positive
impact on patients’ physical functioning and quality of life both before and after LT.
Although 18% of our study patients were found to have COPD as defined by prebronchodilator
FEV1/FVC < 0.70, 80% of these patients did not have a previous clinical diagnosis of COPD.
It may be reasonable, therefore, for all patients evaluated for LT to undergo screening
spirometry. The diagnosis of unsuspected COPD in the LT candidate presents an important
opportunity for a smoking cessation intervention by transplant health professionals. The risks
of respiratory tract cancers, particularly in the setting of posttransplant immunosuppression,
make this an important part of the pretransplant evaluation. Lastly, the impact on functional
status and physical activity–related quality of life makes diagnosis and treatment of COPD
(including smoking cessation) potentially clinically important interventions in a candidate for
LT.
There are some limitations to our study. Our study sample included only patients who were
evaluated for LT and only those with pulmonary function testing and a provided smoking
history. This may have resulted in a selection bias. Although postbronchodilator spirometry is
the gold standard for diagnosing COPD, only prebronchodilator spirometry data were
available. Thus, we may have included patients with other types of obstructive disease (such
as asthma) in our diseased group. We recorded a variety of potential risk factors for COPD;
nonetheless, our findings could be accounted for by another confounding variable or by residual
confounding. Given the relatively small size of our study sample, there was limited power to
detect weaker risk factors for COPD; however, this is the largest study of lung function ever
performed in LT candidates.
In summary, older age and smoking were independently associated with an increased risk of
COPD in patients with advanced liver disease undergoing LT evaluation. Screening and
intervention may be warranted to minimize the short- and long-term impact of COPD in this
patient population.
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COPD chronic obstructive pulmonary disease
DLCOcorr diffusing capacity for carbon monoxide corrected for hemoglobin
FEV1 forced expiratory volume in 1 second
FVC forced vital capacity
LT liver transplantation
MELD Model for End-Stage Liver Disease
OR odds ratio
PBC primary biliary cirrhosis
pCO2 partial pressure of carbon dioxide
pO2 partial pressure of oxygen
PSC primary sclerosing cholangitis
RVSP right ventricular systolic pressure
SF-36 Medical Outcomes Study Short Form-36
References
1. Angueira CE, Kadakia SC. Effects of large-volume paracentesis on pulmonary function in patients
with tense cirrhotic ascites. Hepatology 1994;20:825–828. [PubMed: 7927222]
2. Hourani JM, Bellamy PE, Tashkin DP, Batra P, Simmons MS. Pulmonary dysfunction in advanced
liver disease: frequent occurrence of an abnormal diffusing capacity. Am J Med 1991;90:693–700.
[PubMed: 1904192]
3. Krowka MJ, Dickson ER, Wiesner RH, Krom RA, Atkinson B, Cortese DA. A prospective study of
pulmonary function and gas exchange following liver transplantation. Chest 1992;102:1161–1166.
[PubMed: 1395761]
4. Mohamed R, Freeman JW, Guest PJ, Davies MK, Neuberger JM. Pulmonary gas exchange
abnormalities in liver transplant candidates. Liver Transpl 2002;8:802–808. [PubMed: 12200782]
5. Yao EH, Kong BC, Hsue GL, Zhou AC, Wang H. Pulmonary function changes in cirrhosis of the liver.
Am J Gastroenterol 1987;82:352–354. [PubMed: 3565341]
6. Zein CO, Beatty K, Post AB, Logan L, Debanne S, McCullough AJ. Smoking and increased severity
of hepatic fibrosis in primary biliary cirrhosis: a cross validated retrospective assessment. Hepatology
2006;44:1564–1571. [PubMed: 17133468]
7. Trichopoulos D, MacMahon B, Sparros L, Merikas G. Smoking and hepatitis B-negative primary
hepatocellular carcinoma. J Natl Cancer Inst 1980;65:111–114. [PubMed: 6248671]
8. Pessione F, Ramond MJ, Njapoum C, Duchatelle V, Degott C, Erlinger S, et al. Cigarette smoking and
hepatic lesions in patients with chronic hepatitis C. Hepatology 2001;34:121–125. [PubMed:
11431742]
9. KawutSMKrowkaMJTrotterJFRobertsKEBenzaRLBadeschDBClinical risk factors for
portopulmonary hypertension. Hepatology 2008//10.1002/hep.22275Available at:
http://www3.interscience.wiley.com
10. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to
predict survival in patients with end-stage liver disease. Hepatology 2001;33:464–470. [PubMed:
11172350]
11. Crapo RO, Morris AH. Standardized single breath normal values for carbon monoxide diffusing
capacity. Am Rev Respir Dis 1981;123:185–189. [PubMed: 7235357]
Rybak et al. Page 8













12. Crapo RO, Morris AH, Clayton PD, Nixon CR. Lung volumes in healthy nonsmoking adults. Bull
Eur Physiopathol Respir 1982;18:419–425. [PubMed: 7074238]
13. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general
U.S. population. Am J Respir Crit Care Med 1999;159:179–187. [PubMed: 9872837]
14. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB. Pulmonary-hepatic vascular disorders (PHD).
Eur Respir J 2004;24:861–880. [PubMed: 15516683]
15. Gralnek IM, Hays RD, Kilbourne A, Rosen HR, Keeffe EB, Artinian L, et al. Development and
evaluation of the Liver Disease Quality of Life instrument in persons with advanced, chronic liver
disease—the LDQOL 1.0. Am J Gastroenterol 2000;95:3552–3565. [PubMed: 11151892]
16. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual
framework and item selection. Med Care 1992;30:473–483. [PubMed: 1593914]
17. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis,
management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.
Am J Respir Crit Care Med 2007;176:532–555. [PubMed: 17507545]
18. Mannino DM, Braman S. The epidemiology and economics of chronic obstructive pulmonary disease.
Proc Am Thorac Soc 2007;4:502–506. [PubMed: 17878461]
19. Mannino DM, Doherty DE, Buist SA. Global Initiative on Obstructive Lung Disease (GOLD)
classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities
(ARIC) study. Respir Med 2006;100:115–122. [PubMed: 15893923]
20. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease
surveillance—United States, 1971–2000. MMWR Surveill Summ 2002;51:1–16.
21. Chang SC, Chang HI, Chen FJ, Shiao GM, Wang SS, Lee SD. Therapeutic effects of diuretics and
paracentesis onlung function in patients with non-alcoholic cirrhosis and tense ascites. J Hepatol
1997;26:833–838. [PubMed: 9126796]
22. Chao Y, Wang SS, Lee SD, Shiao GM, Chang HI, Chang SC. Effect of large-volume paracentesis
on pulmonary function in patients with cirrhosis and tense ascites. J Hepatol 1994;20:101–105.
[PubMed: 8201208]
23. Ehlers SL, Rodrigue JR, Widows MR, Reed AI, Nelson DR. Tobacco use before and after liver
transplantation: a single center survey and implications for clinical practice and research. Liver
Transpl 2004;10:412–417. [PubMed: 15004770]
24. Fung JJ, Jain A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B. De novo malignancies after liver
transplantation: a major cause of late death. Liver Transpl 2001;7:S109–S118. [PubMed: 11689783]
25. Oo YH, Gunson BK, Lancashire RJ, Cheng KK, Neuberger JM. Incidence of cancers following
orthotopic liver transplantation in a single center: comparison with national cancer incidence rates
for England and Wales. Transplantation 2005;80:759–764. [PubMed: 16210962]
26. Younossi ZM, Boparai N, Price LL, Kiwi ML, McCormick M, Guyatt G. Health-related quality of
life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol
2001;96:2199–2205. [PubMed: 11467653]
Rybak et al. Page 9

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Rybak et al. Page 12
TABLE 3
Physical Examination and Laboratory Results
Variable n COPD No COPD P Value
Physical examination
 Body mass index, kg/m2 373 27 ± 6 29 ± 6 0.007
 Pulse, beats per minute 372 75 ± 14 77 ± 14 0.41
 Systolic blood pressure, mm Hg 373 123 ± 19 120 ± 18 0.26
 Diastolic blood pressure, mm Hg 373 70 ± 11 70 ± 11 0.82
 Room air oxygen saturation, % 218 97 ± 4 97 ± 3 0.84
 Ascites 368 31 (48%) 113 (37%) 0.12
 Lower extremity edema 368 32 (49%) 165 (54%) 0.44
 Clubbing 363 6 (9%) 26 (9%) 0.90
 Asterixis 366 4 (6%) 19 (6%) 0.96
 Spider angiomata 356 25 (40%) 102 (35%) 0.46
Laboratory results
 Blood urea nitrogen, mg/dL 365 16 ± 9.0 16 ± 12 0.60
 Creatinine, mg/dL 373 1.2 ± 1.0 1.0 ± 1.0 0.37
 Hemoglobin, g/dL 370 12.4 ± 2.2 12.6 ± 2.0 0.46
 Platelet count, 109/L 368 117 ± 63 124 ± 89 0.55
 International normalized ratio 371 1.4 ± 0.3 1.3 ± 0.3 0.24
 Alanine aminotransferase, U/L 372 48 ± 35 55 ± 42 0.18
 Aspartate aminotransferase, U/L 372 71 ± 50 76 ± 48 0.41
 Total bilirubin, mg/dL 373 2.5 ± 2.6 2.8 ± 3.0 0.63
 Alkaline phosphatase, U/L 369 146 ± 70 172 ± 149 0.72
 Total protein, g/dL 358 7.1 ± 0.8 7 ± 0.8 0.52
 Albumin, g/dL 365 3.1 ± 0.6 3.1 ± 0.7 0.60
NOTE: Data are shown as mean ± standard deviation or n (%).
Abbreviation: COPD, chronic obstructive pulmonary disease.
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TABLE 4
Pulmonary Function Testing and Arterial Blood Gas Results
Variable n COPD No COPD P Value
Pulmonary function testing
 Forced vital capacity, % predicted 373 85 ± 19 85 ± 16 0.71
 Forced expiratory volume in 1 second, % predicted 373 69 ± 19 86 ± 16 <0.0001
 Forced expiratory volume in 1 second/forced vital capacity 373 62 ± 8 79 ± 5 <0.0001
 DLCOcorr, % predicted 355 55 ± 13 60 ± 17 0.02
Arterial blood gas
 pH 333 7.44 ± 0.03 7.44 ± 0.04 0.79
 pCO2, mm Hg 333 34 ± 5 35 ± 5 0.69
 pO2, mm Hg 333 81 ± 12 85 ± 16 0.11
 Oxygen saturation, % 326 94 ± 3 95 ± 4 0.72
 Alveolar-arterial oxygen gradient, mm Hg 333 24 (13–31) 15 (7–26) 0.003
NOTE: Data are shown as mean ± standard deviation, median (interquartile range), or n (%).
Abbreviations: COPD, chronic obstructive pulmonary disease; DLCOcorr, diffusing capacity for carbon monoxide corrected for hemoglobin;
pCO2, partial pressure of carbon dioxide; pO2, partial pressure of oxygen.
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TABLE 5
Echocardiography and Chest Radiography Results
Variable n COPD No COPD P Value
Chest radiography
 Cardiomegaly 351 8 (13%) 30 (10%) 0.60
 Large pulmonary arteries 351 2 (3%) 7 (2%) 0.67
 Interstitial lung disease 351 2 (3%) 9 (3%) 1.0
 Hyperinflation 351 2 (3%) 3 (1%) 0.22
 Pleural effusion 351 7 (11%) 46 (16%) 0.33
Echocardiography
 Right atrial dilation 332 10 (17%) 52 (19%) 0.66
 Right ventricular dilation 344 20 (32%) 88 (31%) 0. 95
 Right ventricular hypertrophy 343 12 (19%) 57 (20%) 0.82
 Right ventricular dysfunction 346 6 (9%) 15 (5%) 0.24
 Paradoxical septal motion 324 1 (2%) 2 (1%) 0.47
 Right ventricular systolic pressure, mm Hg 230 44 ± 19 37 ± 13 0.01
 Left atrial size, cm 309 4 ± 1 4 ± 1 0.63
 Left ventricular hypertrophy 349 15 (24%) 91 (32%) 0.24
 Pericardial effusion 341 8 (13%) 33 (12%) 0.81
 Shunting 307 0.46
  None 17 (32%) 91 (36%)
  Intrapulmonary 31 (58%) 150 (59%)
  Intracardiac 5 (9%) 13 (5%)
NOTE: Data are shown as mean ± standard deviation or n (%).
Abbreviation: COPD, chronic obstructive pulmonary disease.
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TABLE 6
Multivariate Logistic Regression
Variable OR 95% CI P Value
Age
 18–47 1.0 — —
 48–53 0.84 0.35–2.03 0.71
 54–59 1.69 0.73–3.90 0.22
 60–79 2.27 1.02–5.06 0.044
Smoking (past or current versus never) 3.74 1.94–7.23 <0.001
Abbreviations: CI, confidence interval; OR, odds ratio.
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TABLE 7
New York Heart Association Functional Class: COPD Versus No COPD (n = 372)
Class COPD No COPD
I 12 (18%) 88 (29%)
II 29 (43%) 138 (45%)
III 25 (37%) 66 (22%)
IV 1 (2%) 13 (4%)
NOTE: Wilcoxon rank sum test, P = 0.03.
Abbreviation: COPD, chronic obstructive pulmonary disease.
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